NCT04481243View on ClinicalTrials.gov

A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

January 20, 2023

Study Completion Date

January 20, 2023

Conditions
Type 1 Diabetes
Interventions
BIOLOGICAL

Pneumovax 23- pneumococcal polysaccharide

PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.

PROCEDURE

Blood draw

6 ml blood draw at baseline and 6 months post immunization

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER